



THERAVECTYS & THE INSTITUT PASTEUR CREATE A JOINT-LAB

*To capitalize on their licensing agreement and boost synergies THERAVECTYS and the INSTITUT PASTEUR have launched a collaborative **JOINT-LAB based on the Lentiviral Vectors Technology Founding-Lab.***

PARIS, October, 10. 2017 – THERAVECTYS, a vaccine company that designs and develops safe and highly efficient T-cell vaccines based on a proprietary lentiviral vector platform, is pleased to announce the consolidation of its long-standing collaboration with the Institut Pasteur through the creation of an R&D Joint-Lab.

Since its incorporation in 2005 and through a global and exclusive license granted by the Institut Pasteur in 2007 to its spin-off created by Dr Pierre Charneau, TheraVectys has controlled, or benefited from, 100% of the rights on lentiviral vectors vaccines. The Joint-Lab between TheraVectys and Institut Pasteur will strengthen the existing connection while supporting the implementation of TheraVectys's Portfolio Strategy in therapeutic and prophylactic vaccination, for infectious, parasitic diseases and oncology.

“Organic collaboration is essential to straight-forward progress”, says Jean Chalopin, CEO. “Sourcing innovation early-on and streamlining developments from early results to fully validated preclinical proof-of concepts and beyond are key steps to building momentum, especially to leverage our broad portfolio of assets. Beyond highly widening and enriching our patents portfolio, the Joint-Lab will ensure optimal resource allocation and quick growth based on synergies. This is the very best ecosystem to achieve the breakthrough promised by the Lentiviral Vectors in the field of vaccination”.

“Collaboration with TheraVectys through the Joint-Lab is a great opportunity for the Institut Pasteur and my team, says Dr. Pierre Charneau, Head of the Joint-Lab, “we shall benefit from industrial support and perspectives to translate our research and results into medicines fully available to patients. It brings our development to the next level and guarantees maximal impact and return on our efforts and investments”.

The Joint-Lab Agreement has been effective since June 7th, 2019, with more than 9 projects already in the collaborative pipeline.

ABOUT THERAVECTYS

THERAVECTYS, a privately-owned vaccine company, translates 20+ years of research on lentiviral vectors into actionable innovation and brings a spectacular paradigm shift in vaccinology. Founded by pioneer inventor Dr. Pierre Charneau, as a spin-off of the Institut Pasteur, TheraVectys leverages a unique proprietary platform to deliver remarkably safe and highly efficient T-cell vaccines as a response to critical unmet medical needs. THERAVECTYS' technology and worldwide license domain has an almost unlimited number of applications in infectious diseases, virally-induced cancers and cancers, and is probably a major silent revolution in vaccination since the discovery of the vaccine against rabies by Louis Pasteur. Our purpose: ‘profoundly transform global health’. Our approach: strategic industrial partnering for leading our PoC-validated vaccine-candidates to clinical trials and to market.

ABOUT THE INSTITUT PASTEUR AND THE INSTITUT PASTEUR INTERNATIONAL NETWORK

The Institut Pasteur, a private foundation with officially recognized charitable status set up by Louis Pasteur in 1887, is today an internationally renowned center for biomedical research with a network of 33 institutes worldwide. In the pursuit of its mission to prevent and fight against diseases in France and throughout the world, the Institut Pasteur operates in four main areas: scientific and medical research, public health and health monitoring, teaching, and business development and technology transfer.

More than 2,500 people work on its Paris campus. The Institut Pasteur is a globally recognized leader in infectious diseases, microbiology, and immunology. Its 130 units also focus their research on certain cancers, genetic and neurodegenerative diseases, genomics and developmental biology. This research aims to expand our knowledge of living organisms in a bid to lay the foundation for new prevention strategies and novel therapeutics. Since its inception, 10 Institut Pasteur scientists have been awarded the Nobel Prize for Medicine, including two in 2008 for the 1983 discovery of the human immunodeficiency virus (HIV) that causes AIDS.

With a portfolio of 350 patent families, 24 new spin-off companies, and over 170 license/sublicense and research agreements in the fields of diagnostics, vaccines and therapeutics, the Institut Pasteur plays a major role in technology transfer activities that directly benefit patients and generate significant resources to further support its research activities.

For more information

+33 1 43 90 19 20

contact@theravectys.com



THERAVECTYS - Institut Pasteur, Bât P Biotop, 28 rue du Docteur Roux, 75724 Paris Cedex 15, FRANCE - SA Capital: 147 356,20 EUR

www.theravectys.com